AdPEDF gene therapy

Drug Profile

AdPEDF gene therapy

Alternative Names: Ad35 adenovector delivery; Ad35PEDF; AdGVPEDF.11D; AdPEDF; AdPEDF.11D; Blindness prevention programme - GenVac; PEDF gene therapy; Pigment epithelium-derived factor gene therapy - GenVec

Latest Information Update: 17 May 2011

Price : $50

At a glance

  • Originator National Institutes of Health (USA); Northwestern University
  • Developer GenVec
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Age-related macular degeneration; Diabetic retinopathy

Most Recent Events

  • 21 May 2008 GenVec receives grant from National Eye Institute for AdPEDF gene therapy development in wet AMD
  • 29 Feb 2008 Phase I evaluation is ongoing for Age-related macular degeneration
  • 14 May 2007 Preclinical data added to the Eye Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top